Assessing Hearing Loss in Chronic Myeloid Leukemia Treatments

Why It Matters

Hearing loss can impair quality of life and treatment adherence, making early detection crucial for sustaining therapeutic outcomes in CML patients.

Key Takeaways

• 7% ototoxicity observed in CML TKI cohort
• High‑frequency loss linked to cumulative drug exposure
• Second‑generation TKIs show higher risk than imatinib
• Routine audiometry enables dose adjustment, preserving hearing

Pulse Analysis

The emergence of targeted therapies has transformed chronic myeloid leukemia treatment, yet the long‑term safety profile of tyrosine‑kinase inhibitors (TKIs) remains under scrutiny. Recent evidence highlights ototoxicity as a previously under‑recognized adverse effect, particularly with second‑generation agents such as dasatinib and nilotinib. By integrating comprehensive audiometric assessments into clinical trials, researchers quantified a 7% incidence of clinically relevant hearing loss, a figure that surpasses earlier anecdotal reports. This data underscores the need for oncologists to balance efficacy with sensory health, especially as patients often remain on therapy for decades.

From a mechanistic perspective, TKIs may disrupt cochlear blood flow and interfere with cellular signaling pathways essential for hair cell maintenance. High‑frequency thresholds are the first to deteriorate, mirroring patterns seen with other ototoxic drugs like cisplatin. Importantly, the study demonstrated a dose‑response relationship, suggesting that cumulative exposure, rather than a single event, drives auditory decline. These insights pave the way for risk‑stratified monitoring, where patients on higher‑risk TKIs receive more frequent hearing tests and clinicians consider dose reductions or drug switches at the earliest sign of impairment.

For healthcare systems, incorporating routine audiology into CML care pathways could reduce downstream costs associated with hearing rehabilitation and improve patient adherence. Payers may view proactive monitoring as a value‑based intervention, aligning with broader initiatives to mitigate chronic therapy side effects. As the oncology community embraces precision medicine, expanding safety surveillance to include sensory outcomes will be essential for delivering holistic, patient‑centered care.